IDYA vs KURA
IDYA: IDEAYA Biosciences is a clinical-stage precision medicine company focused on discovering and developing targeted synthetic lethality therapies for oncology. KURA: Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
Side-by-side fundamentals
| Metric | IDYA | KURA | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $39.67 | $11.89 | |
| Market cap as of 2026-08-24 | $3.8B | $1.1B | |
| PEG as of 2026-08-24 | n/a | -0.07 | |
| Net margin as of 2026-08-24 | -74.8% | -411.2% | IDYA higher |
| Gross margin as of 2026-08-24 | n/a | +99.9% | |
| Operating margin as of 2026-08-24 | -92.7% | -443.5% | IDYA higher |
| ROE as of 2026-08-24 | -16.5% | -141.9% | IDYA higher |
| ROA as of 2026-08-24 | -15.1% | -43.3% | IDYA higher |
| Debt / equity as of 2026-08-24 | 0.00 | 0.09 | IDYA lower |
| Revenue growth (YoY) as of 2026-08-24 | +3118.1% | +29.5% | IDYA higher |
| Revenue CAGR (3y) SEC XBRL | +62.5% | n/a | |
| Beta as of 2026-08-24 | -0.06 | 0.43 | |
| 1-year return as of 2026-08-21 close | +61.1% | +59.8% | IDYA higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.